Boston Scientific Corp. launched its first trial for a fully bioresorbable coronary scaffold recently, but executives suggest the firm is treading carefully to see if it offers sufficient advantage
The cardiology sector has long been one of the most innovative in medtech, with technologies such as drug-eluting stents (DES) and transcatheter aortic valves cutting down the need for more invasive o
Boston Scientific Corp. is stepping up efforts to enter the growing fractional flow reserve interventional cardiology market, inking a development agreement with Japanese guidewire-maker Asahi Int
The year 2014 was a heady one for medtech M&A, with bigger deals and more invested in them than ever before – $89.3 billion, according to Informa’s Strategic Transactions . A lot of the 2014 M&A impe